Skip to main content
  • DOACs Prevail in Cancer VTE Trials - Bleeding data complicate efficacy benefits

    ATLANTA -- Two different direct oral anticoagulants (DOACs) proved to be at least equivalent to low molecular weight heparin (LMWH) for preventing venous thromboembolism (VTE) in patients with cancer, according to studies reported here.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details